Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 77
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker BTEE(USD) LSE
ETF Ticker BTEE.L(GBP) LSE

Holdings detail for HALO

Stock Name	Halozyme Therapeutics Inc
Ticker	HALO(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US40637H1095
LEI	529900242I3SV9AGM753

Show aggregate HALO holdings

News associated with HALO

Notable ETF Outflow Detected - XBI, ALNY, HALO, INSM: Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $119.6 million dollar outflow -- that's a 2.2% decrease week over week - 2025-08-28 11:56:11
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Consensus Recommendation of “Hold” from Analysts: Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) has been assigned a consensus rating of “Hold” from the eleven research firms that are covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation and four have issued a buy recommendation on the […] - 2025-08-26 02:16:51
Halozyme Therapeutics (NASDAQ:HALO) Sets New 52-Week High Following Analyst Upgrade: Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Tuesday after Morgan Stanley raised their price target on the stock from $75.00 to $80.00. Morgan Stanley currently has an overweight rating on the stock. Halozyme Therapeutics traded as high as $70.70 and last traded at […] - 2025-08-20 02:34:49
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Position Lessened by Vanguard Group Inc.: Vanguard Group Inc. trimmed its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 3.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,831,503 shares of the biopharmaceutical company’s stock after selling 450,211 shares during […] - 2025-08-13 05:43:01
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Charles Schwab Investment Management Inc.: Charles Schwab Investment Management Inc. decreased its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 1.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,748,851 shares of the biopharmaceutical company’s stock after selling 34,326 shares during […] - 2025-08-12 05:24:49
Halozyme Therapeutics (NASDAQ:HALO) Upgraded to “Overweight” at Morgan Stanley: Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) was upgraded by analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating in a report released on Wednesday, Marketbeat Ratings reports. The brokerage currently has a $75.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $62.00. Morgan Stanley’s […] - 2025-08-08 02:40:46
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock Holdings Boosted by LPL Financial LLC: LPL Financial LLC lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 17.1% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 242,432 shares of the biopharmaceutical company’s stock after acquiring an additional 35,429 shares during the period. LPL Financial LLC’s holdings in […] - 2025-08-07 04:46:47
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives $62.70 Consensus Price Target from Analysts: Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) have earned an average recommendation of “Hold” from the twelve analysts that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating on the company. […] - 2025-08-04 02:59:02
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Acquired by IFP Advisors Inc: IFP Advisors Inc increased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 2,374.1% during the first quarter, HoldingsChannel.com reports. The fund owned 2,103 shares of the biopharmaceutical company’s stock after buying an additional 2,018 shares during the period. IFP Advisors Inc’s holdings in Halozyme Therapeutics were worth $134,000 as of its most […] - 2025-07-29 04:32:50
Envestnet Asset Management Inc. Acquires 1,161 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO): Envestnet Asset Management Inc. raised its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 0.4% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 303,774 shares of the biopharmaceutical company’s stock after acquiring an additional 1,161 shares during […] - 2025-07-17 04:50:57
Teacher Retirement System of Texas Sells 3,278 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO): Teacher Retirement System of Texas trimmed its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 8.7% in the first quarter, Holdings Channel reports. The institutional investor owned 34,238 shares of the biopharmaceutical company’s stock after selling 3,278 shares during the quarter. Teacher Retirement System of Texas’ holdings in Halozyme Therapeutics were worth $2,185,000 […] - 2025-07-10 05:14:10
Analysts Set Halozyme Therapeutics, Inc. (NASDAQ:HALO) PT at $61.90: Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) has received a consensus rating of “Hold” from the twelve research firms that are covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating on the company. The average […] - 2025-07-10 03:07:07
Principal Financial Group Inc. Has $24.25 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO): Principal Financial Group Inc. grew its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 1.0% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 380,021 shares of the biopharmaceutical company’s stock after buying an additional 3,826 shares during the quarter. Principal Financial Group […] - 2025-07-09 05:51:39
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Vontobel Holding Ltd.: Vontobel Holding Ltd. decreased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 39.9% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 4,742 shares of the biopharmaceutical company’s stock after selling 3,153 shares during the quarter. Vontobel Holding Ltd.’s holdings in Halozyme […] - 2025-07-09 05:00:49
Envestnet Portfolio Solutions Inc. Has $721,000 Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO): Envestnet Portfolio Solutions Inc. lowered its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 35.2% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 11,292 shares of the biopharmaceutical company’s stock after selling 6,143 shares during the period. Envestnet Portfolio Solutions Inc.’s […] - 2025-06-26 04:38:48
Janney Montgomery Scott LLC Grows Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO): Janney Montgomery Scott LLC boosted its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 2.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 294,123 shares of the biopharmaceutical company’s stock after purchasing an additional 6,392 shares during […] - 2025-06-19 05:50:56
SeaCrest Wealth Management LLC Invests $213,000 in Halozyme Therapeutics, Inc. (NASDAQ:HALO): SeaCrest Wealth Management LLC purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 3,333 shares of the biopharmaceutical company’s stock, valued at approximately $213,000. Several other institutional […] - 2025-06-09 05:54:51
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Wellington Management Group LLP: Wellington Management Group LLP lessened its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 12.0% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 57,370 shares of the biopharmaceutical company’s stock after selling 7,787 shares during the quarter. Wellington Management Group LLP’s holdings in Halozyme Therapeutics were worth $2,743,000 at the […] - 2025-06-06 05:34:51
Tidal Investments LLC Has $381,000 Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO): Tidal Investments LLC trimmed its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 61.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,978 shares of the biopharmaceutical company’s stock after selling 12,598 shares during the period. Tidal Investments LLC’s holdings […] - 2025-05-30 05:47:04
Friday's ETF with Unusual Volume: GFLW: The VictoryShares Free Cash Flow Growth ETF is seeing unusually high volume in afternoon trading Friday, with over 2.9 million shares traded versus three month average volume of about 196,000. Shares of GFLW were up about 0.7% on the day. Components of that ETF with the highes - 2025-05-16 16:18:34
Baird Financial Group Inc. Buys 221 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO): Baird Financial Group Inc. raised its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 2.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,119 shares of the biopharmaceutical company’s stock after acquiring an additional 221 shares during the period. […] - 2025-05-16 05:31:14
Halozyme Therapeutics Reaches Analyst Target Price: In recent trading, shares of Halozyme Therapeutics Inc (Symbol: HALO) have crossed above the average analyst 12-month target price of $68.12, changing hands for $70.14/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgra - 2025-05-08 09:19:58
Hsbc Holdings PLC Acquires 3,289 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO): Hsbc Holdings PLC increased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 52.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 9,615 shares of the biopharmaceutical company’s stock after purchasing an additional 3,289 shares during the quarter. Hsbc […] - 2025-05-08 05:10:47
Halozyme Therapeutics (NASDAQ:HALO) Sets New 12-Month High After Strong Earnings: Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report)’s share price reached a new 52-week high during mid-day trading on Wednesday following a stronger than expected earnings report. The company traded as high as $69.07 and last traded at $68.06, with a volume of 1856311 shares trading hands. The stock had previously closed at $59.38. The […] - 2025-05-08 03:08:54
4,426 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Acquired by Marshall Wace LLP: Marshall Wace LLP bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) during the 4th quarter, Holdings Channel.com reports. The fund bought 4,426 shares of the biopharmaceutical company’s stock, valued at approximately $212,000. Other institutional investors and hedge funds have also made changes to their positions in the company. Heck […] - 2025-05-06 04:30:49
Halozyme Files Patent Infringement Lawsuit Against Merck: (RTTNews) - Halozyme Therapeutics (HALO) filed a patent infringement lawsuit against Merck Sharp & Dohme Corp. in U.S. District Court in New Jersey. Halozyme believes the subcutaneous formulation of Merck's cancer medicine, Keytruda, infringes multiple patents that Halozyme filed - 2025-04-24 10:08:04
Legal & General Group Plc Decreases Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO): Legal & General Group Plc lowered its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 1.4% in the fourth quarter, HoldingsChannel.com reports. The fund owned 225,427 shares of the biopharmaceutical company’s stock after selling 3,197 shares during the quarter. Legal & General Group Plc’s holdings in Halozyme Therapeutics were worth $10,778,000 […] - 2025-04-17 06:08:53
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by CIBC Private Wealth Group LLC: CIBC Private Wealth Group LLC lessened its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 99.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,053 shares of the biopharmaceutical company’s stock after selling 963,451 shares during […] - 2025-04-08 05:22:55
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by California Public Employees Retirement System: California Public Employees Retirement System cut its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 6.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 213,687 shares of the biopharmaceutical company’s stock after selling 15,172 shares during the quarter. […] - 2025-04-07 05:56:55
Schroder Investment Management Group Sells 9,933,836 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO): Schroder Investment Management Group cut its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 99.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 87,503 shares of the biopharmaceutical company’s stock after selling 9,933,836 shares during the quarter. Schroder Investment Management […] - 2025-04-06 05:30:52

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) HALO holdings

Date	Number of HALO Shares Held	Base Market Value of HALO Shares	Local Market Value of HALO Shares	Change in HALO Shares Held	Change in HALO Base Value	Current Price per HALO Share Held	Previous Price per HALO Share Held
2025-11-11 (Tuesday)	75,627	USD 5,303,722	USD 5,303,722	0	USD 160,330	USD 70.13	USD 68.01
2025-11-10 (Monday)	75,627	USD 5,143,392	USD 5,143,392	193	USD -4,224	USD 68.01	USD 68.24
2025-11-07 (Friday)	75,434	USD 5,147,616	USD 5,147,616	0	USD -11,315	USD 68.24	USD 68.39
2025-11-06 (Thursday)	75,434	USD 5,158,931	USD 5,158,931	193	USD 19,971	USD 68.39	USD 68.3
2025-11-05 (Wednesday)	75,241	USD 5,138,960	USD 5,138,960	0	USD 18,810	USD 68.3	USD 68.05
2025-11-04 (Tuesday)	75,241	USD 5,120,150	USD 5,120,150	194	USD 152,039	USD 68.05	USD 66.2
2025-11-03 (Monday)	75,047	USD 4,968,111	USD 4,968,111	0	USD 75,797	USD 66.2	USD 65.19
2025-10-31 (Friday)	75,047	USD 4,892,314	USD 4,892,314	0	USD 42,026	USD 65.19	USD 64.63
2025-10-30 (Thursday)	75,047	USD 4,850,288	USD 4,850,288	970	USD 16,023	USD 64.63	USD 65.26
2025-10-29 (Wednesday)	74,077	USD 4,834,265	USD 4,834,265	388	USD 15,004	USD 65.26	USD 65.4
2025-10-28 (Tuesday)	73,689	USD 4,819,261	USD 4,819,261	0	USD -33,160	USD 65.4	USD 65.85
2025-10-27 (Monday)	73,689	USD 4,852,421	USD 4,852,421	0	USD -22,106	USD 65.85	USD 66.15

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of HALO by Blackrock for IE00BDZVHG35

Show aggregate share trades of HALO

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-11-10 BUY 193 69.390 67.980 68.121 USD 13,147 58.47
2025-11-06 BUY 193 70.490 67.395 67.704 USD 13,067 58.36
2025-11-04 BUY 194 69.910 65.000 65.491 USD 12,705 58.26
2025-10-30 BUY 970 66.240 63.950 64.179 USD 62,254 58.14
2025-10-29 BUY 388 65.260 66.970 66.799 USD 25,918 58.10
2025-10-22 SELL -776 65.770 67.360 67.201 USD -52,148 57.88 Loss of -7,237 on sale
2025-10-20 BUY 388 66.470 67.270 67.190 USD 26,070 57.77
2025-10-17 BUY 969 67.030 67.540 67.489 USD 65,397 57.72
2025-10-15 BUY 1,544 66.360 67.620 67.494 USD 104,211 57.67
2025-10-03 BUY 1,344 68.980 71.840 71.554 USD 96,169 57.55
2025-10-02 BUY 192 71.690 75.500 75.119 USD 14,423 57.47
2025-09-30 BUY 384 73.340 74.930 74.771 USD 28,712 57.27
2025-09-26 BUY 384 73.750 75.250 75.100 USD 28,838 57.07
2025-09-25 BUY 384 73.970 75.590 75.428 USD 28,964 56.97
2025-09-18 BUY 212 76.680 76.980 76.950 USD 16,313 56.85
2025-09-17 BUY 639 75.810 76.610 76.530 USD 48,903 56.73
2025-09-11 SELL -213 77.530 77.580 77.575 USD -16,523 56.48 Loss of -4,493 on sale
2025-09-10 BUY 426 75.800 76.340 76.286 USD 32,498 56.36
2025-07-17 SELL -426 57.810 58.560 58.485 USD -24,915 56.22 Loss of -963 on sale
2025-07-16 BUY 709 58.010 58.450 58.406 USD 41,410 56.21
2025-07-11 SELL -1,688 57.150 57.860 57.789 USD -97,548 56.19 Loss of -2,691 on sale
2025-07-02 BUY 11,605 53.840 54.250 54.209 USD 629,095 56.21
2025-06-25 BUY 422 52.320 53.640 53.508 USD 22,580 56.32
2025-06-20 BUY 1,820 52.810 53.750 53.656 USD 97,654 56.39
2025-06-11 BUY 410 53.850 55.600 55.425 USD 22,724 56.53
2025-06-10 BUY 410 53.770 54.510 54.436 USD 22,319 56.56
2025-06-04 SELL -205 53.850 54.110 54.084 USD -11,087 56.63 Profit of 523 on sale
2025-04-23 BUY 204 58.410 59.230 59.148 USD 12,066 56.38
2025-04-10 SELL -1,632 57.700 59.640 59.446 USD -97,016 56.10 Loss of -5,458 on sale
2025-04-08 SELL -204 57.540 61.370 60.987 USD -12,441 56.03 Loss of -1,011 on sale
2025-04-07 SELL -204 59.350 61.820 61.573 USD -12,561 55.99 Loss of -1,138 on sale
2025-04-04 SELL -1,020 59.770 60.980 60.859 USD -62,076 55.95 Loss of -5,007 on sale
2025-04-01 BUY 1,773 61.870 64.170 63.940 USD 113,366 55.79
2025-03-31 SELL -603 63.810 64.070 64.044 USD -38,619 55.70 Loss of -5,034 on sale
2025-03-21 BUY 723 65.160 65.210 65.205 USD 47,143 55.01
2025-03-14 SELL -3,184 62.270 62.720 62.675 USD -199,557 54.43 Loss of -26,253 on sale
2025-03-07 SELL -398 60.980 61.490 61.439 USD -24,453 53.92 Loss of -2,993 on sale
2025-03-04 SELL -199 58.140 58.660 58.608 USD -11,663 53.66 Loss of -984 on sale
2025-02-25 BUY 398 57.990 58.980 58.881 USD 23,435 53.28
2025-02-19 SELL -199 57.770 60.670 60.380 USD -12,016 52.94 Loss of -1,481 on sale
2025-02-13 BUY 597 58.610 58.720 58.709 USD 35,049 52.51
2025-02-12 BUY 199 58.110 58.330 58.308 USD 11,603 52.40
2025-02-11 BUY 796 57.330 57.390 57.384 USD 45,678 52.30
2024-12-30 SELL -6,765 47.990 48.800 48.719 USD -329,584 50.88 Profit of 14,603 on sale
2024-11-18 SELL -3,255 42.570 45.710 45.396 USD -147,764 54.38 Profit of 29,255 on sale
2024-11-08 SELL -217 60.980 61.190 61.169 USD -13,274 53.54 Loss of -1,656 on sale
2024-10-21 SELL -217 51.770 52.770 52.670 USD -11,429 0.00 Loss of -11,429 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-11-10	BUY	193	69.390	67.980	68.121	USD 13,147	58.47
2025-11-06	BUY	193	70.490	67.395	67.704	USD 13,067	58.36
2025-11-04	BUY	194	69.910	65.000	65.491	USD 12,705	58.26
2025-10-30	BUY	970	66.240	63.950	64.179	USD 62,254	58.14
2025-10-29	BUY	388	65.260	66.970	66.799	USD 25,918	58.10
2025-10-22	SELL	-776	65.770	67.360	67.201	USD -52,148	57.88 Loss of -7,237 on sale
2025-10-20	BUY	388	66.470	67.270	67.190	USD 26,070	57.77
2025-10-17	BUY	969	67.030	67.540	67.489	USD 65,397	57.72
2025-10-15	BUY	1,544	66.360	67.620	67.494	USD 104,211	57.67
2025-10-03	BUY	1,344	68.980	71.840	71.554	USD 96,169	57.55
2025-10-02	BUY	192	71.690	75.500	75.119	USD 14,423	57.47
2025-09-30	BUY	384	73.340	74.930	74.771	USD 28,712	57.27
2025-09-26	BUY	384	73.750	75.250	75.100	USD 28,838	57.07
2025-09-25	BUY	384	73.970	75.590	75.428	USD 28,964	56.97
2025-09-18	BUY	212	76.680	76.980	76.950	USD 16,313	56.85
2025-09-17	BUY	639	75.810	76.610	76.530	USD 48,903	56.73
2025-09-11	SELL	-213	77.530	77.580	77.575	USD -16,523	56.48 Loss of -4,493 on sale
2025-09-10	BUY	426	75.800	76.340	76.286	USD 32,498	56.36
2025-07-17	SELL	-426	57.810	58.560	58.485	USD -24,915	56.22 Loss of -963 on sale
2025-07-16	BUY	709	58.010	58.450	58.406	USD 41,410	56.21
2025-07-11	SELL	-1,688	57.150	57.860	57.789	USD -97,548	56.19 Loss of -2,691 on sale
2025-07-02	BUY	11,605	53.840	54.250	54.209	USD 629,095	56.21
2025-06-25	BUY	422	52.320	53.640	53.508	USD 22,580	56.32
2025-06-20	BUY	1,820	52.810	53.750	53.656	USD 97,654	56.39
2025-06-11	BUY	410	53.850	55.600	55.425	USD 22,724	56.53
2025-06-10	BUY	410	53.770	54.510	54.436	USD 22,319	56.56
2025-06-04	SELL	-205	53.850	54.110	54.084	USD -11,087	56.63 Profit of 523 on sale
2025-04-23	BUY	204	58.410	59.230	59.148	USD 12,066	56.38
2025-04-10	SELL	-1,632	57.700	59.640	59.446	USD -97,016	56.10 Loss of -5,458 on sale
2025-04-08	SELL	-204	57.540	61.370	60.987	USD -12,441	56.03 Loss of -1,011 on sale
2025-04-07	SELL	-204	59.350	61.820	61.573	USD -12,561	55.99 Loss of -1,138 on sale
2025-04-04	SELL	-1,020	59.770	60.980	60.859	USD -62,076	55.95 Loss of -5,007 on sale
2025-04-01	BUY	1,773	61.870	64.170	63.940	USD 113,366	55.79
2025-03-31	SELL	-603	63.810	64.070	64.044	USD -38,619	55.70 Loss of -5,034 on sale
2025-03-21	BUY	723	65.160	65.210	65.205	USD 47,143	55.01
2025-03-14	SELL	-3,184	62.270	62.720	62.675	USD -199,557	54.43 Loss of -26,253 on sale
2025-03-07	SELL	-398	60.980	61.490	61.439	USD -24,453	53.92 Loss of -2,993 on sale
2025-03-04	SELL	-199	58.140	58.660	58.608	USD -11,663	53.66 Loss of -984 on sale
2025-02-25	BUY	398	57.990	58.980	58.881	USD 23,435	53.28
2025-02-19	SELL	-199	57.770	60.670	60.380	USD -12,016	52.94 Loss of -1,481 on sale
2025-02-13	BUY	597	58.610	58.720	58.709	USD 35,049	52.51
2025-02-12	BUY	199	58.110	58.330	58.308	USD 11,603	52.40
2025-02-11	BUY	796	57.330	57.390	57.384	USD 45,678	52.30
2024-12-30	SELL	-6,765	47.990	48.800	48.719	USD -329,584	50.88 Profit of 14,603 on sale
2024-11-18	SELL	-3,255	42.570	45.710	45.396	USD -147,764	54.38 Profit of 29,255 on sale
2024-11-08	SELL	-217	60.980	61.190	61.169	USD -13,274	53.54 Loss of -1,656 on sale
2024-10-21	SELL	-217	51.770	52.770	52.670	USD -11,429	0.00 Loss of -11,429 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of HALO

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	371,468	246	613,712	60.5%
2025-09-18	369,209	50	726,194	50.8%
2025-09-17	256,611	9,792	553,701	46.3%
2025-09-16	228,403	90	394,052	58.0%
2025-09-15	227,697	268	471,461	48.3%
2025-09-12	221,090	110	427,510	51.7%
2025-09-11	514,076	1,959	993,633	51.7%
2025-09-10	166,289	386	439,002	37.9%
2025-09-09	273,054	401	595,146	45.9%
2025-09-08	673,482	7,545	952,324	70.7%
2025-09-05	290,024	13,523	686,839	42.2%
2025-09-04	407,737	5,358	712,769	57.2%
2025-09-03	550,404	13,706	1,063,453	51.8%
2025-09-02	616,278	11,835	991,442	62.2%
2025-08-29	269,930	76,054	395,068	68.3%
2025-08-28	433,760	4,556	628,921	69.0%
2025-08-27	1,260,611	4,539	1,702,449	74.0%
2025-08-26	588,702	2,967	980,200	60.1%
2025-08-25	371,565	2,132	648,270	57.3%
2025-08-22	876,545	177,507	1,274,834	68.8%
2025-08-21	443,688	60,024	724,496	61.2%
2025-08-20	591,075	169,034	869,550	68.0%
2025-08-19	935,006	12,421	1,715,495	54.5%
2025-08-18	449,801	7,338	718,194	62.6%
2025-08-15	329,469	7,019	525,006	62.8%
2025-08-14	516,843	66,827	759,578	68.0%
2025-08-13	389,927	5,826	908,606	42.9%
2025-08-12	781,374	13,603	1,175,102	66.5%
2025-08-11	586,472	59,410	817,358	71.8%
2025-08-08	285,728	19,152	668,999	42.7%
2025-08-07	408,493	14	863,233	47.3%
2025-08-06	1,204,156	4,850	2,539,387	47.4%
2025-08-05	583,045	290	1,069,043	54.5%
2025-08-04	177,608	200	363,851	48.8%
2025-08-01	207,308	307	616,187	33.6%
2025-07-31	622,123	147	1,098,496	56.6%
2025-07-30	274,323	1,375	540,028	50.8%
2025-07-29	318,079	3,010	584,122	54.5%
2025-07-28	194,988	129	416,263	46.8%
2025-07-25	115,024	0	312,074	36.9%
2025-07-24	144,854	26,732	266,453	54.4%
2025-07-23	154,871	30,676	443,144	34.9%
2025-07-22	203,247	0	381,321	53.3%
2025-07-21	144,964	1,656	318,072	45.6%
2025-07-18	136,030	1,809	379,301	35.9%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	BTEE(USD) LSE
ETF Ticker	BTEE.L(GBP) LSE